The delusion around Directors' participation in the February 23 placement continues.
I can see an enormous issue for Directors IMO if they don't participate and it all goes to pot as one of the company's disclosures appears defective
i.e. the 9 Feb 23 announcement re completion of capital raising and their "cornerstone support" to the placement, or the Form F-1 re Related Party Transactions where they don't disclose this commitment?
Ann: CardieX Files Form F-1 to Dual List on US Nasdaq Exchange, page-33
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
